Summary
A mid-size, top 5 European pharmaceutical company engaged PRA in a global Phase III study in 20 countries on patients with advanced breast cancer previously treated with or resistant to airmaximus an anthracycline and who are taxane resistant. By identifying optimal sites in in Russia, Ukraine, Belarus, and Estonia, PRA recruited 318 patients at 25 sites, compared to 450+ patients at 150 sites in Rest of World (ROW).
Register to download
Optimal Recruitment Strategies
You may also be interested in:
Case Study
Strong Site Selection Leads To Success
A randomized, double-blind, placebo-controlled Phase III study of Study Drug versus placebo for patients with advanced gastrointestinal stromal…
White Paper
Translating Cancer Genomics Into a Personalized Approach For Cancer Patients
This white paper provides a brief history of oncology genomics, including development, uses in improving patient care, current achievements and…
Case Study
Recruiting Solid Tumor Patients in a Complex ADME Trial
PRA's PPS facility in Budapest (PPS-Hungary) was contracted to run an open-label, non-randomized, Phase I study to characterize the mass balance and…